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Abstract
Objective This study was aimed at estimating type-specific
HPV prevalence and its cofactors among Honduran women
with normal cytology in order to provide valuable infor-
mation to health policymakers about the epidemiology of
this important sexually transmitted infection.
Methods A total of 591 women with normal cytology
from Tegucigalpa, Honduras were interviewed and tested
for HPV using the SPF10 LiPA25. A structured epidemi-
ological questionnaire was administered to each woman.
Results The overall HPV prevalence was 51%. Twenty-
three types of HPV were detected; HPV 16, 51, 31, 18, and
11 were the most common. The highest prevalence of
cancer associated HPV types (15.0%) was found in the
women less than 35 years. Besides the association with
age, the main independent predictors of HPV infection
were the lifetime number of sexual partners and having a
low socioeconomic status and less than 5 previous Pap
smears.
Conclusions In the population studied, there was a broad
diversity of HPV infections, with high-risk types being the
most common types detected. The establishment of a well-
characterized population with regard to the community
prevalence of type-specific HPV infection will provide a
valuable baseline for monitoring population effectiveness
of an HPV vaccine.
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Introduction
Carcinoma of the cervix is the most common type of cancer
in the developing world and the leading cause of death
from cancer among women. The estimated new cervical
cancer cases per year is 500,000 [1], 80% of which is
occurring in the developing countries [2]. In Central and
South America, the incidence rate is about 5 times as high
as in Western Europe [3]. In Honduras, cancer of the cervix
is a major public health problem and also has the highest
mortality rates due to cancer among women with a cervical
cancer age standardized rate of 30.6/100,000 inhabitants
[4].
There is overwhelming data from multiple epidemiologic
and laboratory studies demonstrating the central etiologic
role of human papillomavirus (HPV) in cervical cancer
[5–10].
It is necessary to understand the global burden of HPV
infections in order to establish effective prevention strate-
gies such as improved screening programs, public health
education, and vaccines [11]. In this context, surveys to
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determine HPV prevalence in different age groups and
circulating genotypes in the population are needed to
understand the wide variations in the incidence of cervical
cancer in populations worldwide. These will contribute to
establish the proportion of women that could be effectively
protected by vaccination.
Despite the high incidence of cervical cancer reported
from Honduras, population-based studies on the HPV
prevalence and genotype distribution are scarce [12, 13]. It
is of fundamental importance to get insight into the
development of this disease in order to design effective
strategies to treat and prevent cervical carcinoma and its
related mortality and morbidity.
This study was aimed at determining type-specific HPV
prevalence and its cofactors among Honduran women with
normal cytology in order to provide valuable information
to health policymakers about the epidemiology of this
sexually transmitted infection.
Methods
Study population and collection of specimens
The study population included a sample of 591 women,
randomly selected, attending a communal cervical cancer
screening centers and family planning clinics in low-
medium socioeconomic settings in Tegucigalpa, the capital
city of Honduras. In general, women may be referred for
screening by their physicians or request screening on their
own accord. Eligible women were those between 18 and
65 years of age, identified as being resident for at least
6 months in Tegucigalpa, without a history of preneoplasic
or neoplasic lesions of the cervix, conization or hysterec-
tomy, not currently pregnant, who were willing to partici-
pate and who signed an informed consent form.
The nature of the study was explained to the patients
by trained medical staff
A thorough physical examination was performed, and a
structured epidemiological questionnaire was administered
to each woman. Questions pertained to sociodemographic
variables like age, occupation, education level, smoking;
contraceptive use, previous cervical smear history and
exposure to wood smoke and also questions regarding
sexual behavior to gain insight into risk factors for
acquiring HPV were asked. The interviews lasted approx-
imately 15 min. Assurance of confidentiality was obtained
by gathering some of the information in two different
questions and at the end of each interview the interviewer
could address if the information given by the patient was
reliable and if she appeared confident.
The study was reviewed and approved by the
correspondent ethical committee
Five women did no consent to participate
in the study (\1%)
An Ayre spatula was used to obtain a cervical smear, which
was immediately fixed for cytological examination. Fol-
lowing the Pap collection, additional material was
obtained from the cervix for HPV analysis and placed in
5 mL sterile phosphate-buffered saline (PBS, 0.82% (w/v);
NaCl, 0.19% (w/v); Na2HPO42H2O, 0.03% (w/v); NaH2-
PO42H2O, adjusted to pH 7.4 with HCL 1 M) 0.005% thi-
merosal. Upon arrival in the laboratory, cells were vortexed,
centrifuged for 10 min at 4,500 rpm, then resuspended in
1 mL of PBS and centrifuged again for 10 min at 4,500 rpm,
resuspended in 0.5 mL of PBS and stored at -20C for
further analysis. Extreme caution was taken to prevent cross-
contamination of specimens. Pap smears were all reviewed
by the same pathologist. Six women were excluded due to
abnormal cytology results (1%).
HPV DNA detection
DNA extraction and HPV-PCR assay
DNA extraction from the cervical cells was performed
according to the Boom method as previously described
[14]. Two hundred microliters of material was isolated and
resuspended in a final volume of 100 lL; an extraction
control consisting of nuclease free water was placed after
every 5th sample. About 10 lL of sample DNA or control
were used for each of the various PCR analyses.
All samples were prescreened with the b-globin primers
PCO3/PCO5 to assess sample integrity.
All work was performed in a laminar flow hood in a
dedicated room free from plasmid DNA.
HPV SPF10 Line Blot25 assay
(i) PCR amplification of HPV DNA. Broad-spectrum HPV
DNA amplification was performed using a short PCR
fragment assay (HPV SPF10 Line Blot25 assay Labo Bio-
medical products B. V. Rijswijk, The Netherlands). This
assay amplifies a 65-bp fragment of the L1 open reading
frame, and allows detection of at least 43 different HPV
types. SPF10 PCR system was performed in a final reaction
volume of 50 lL, containing 10 lL of the isolated DNA
sample and 40 lL PCR mix, containing 10 mmol/L Tris–
HCL (pH 9.0), 50 mmol/L KCL, 2.0 mmol/L MgCl2, 0.1%
Triton X-100, 0.01% gelatine, 200 lmol/L of each
deoxynucleoside triphosphate (dATP, dCTP, dGTP, and
dTTP), 15 pmol each of the forward and reverse primers
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tagged with biotin at the 50 end, and 1.5 units of AmpliTaq
Gold (Applied Biosystems, Foster City, CA, USA).
Activation of AmpliTaq Gold for 9 min at 94C was fol-
lowed by 40 cycles of 30 s at 94C, 45 s at 52C and 45 s
at 72C, with a final extension of 5 min at 72C. Appro-
priate negative and positive controls were used to monitor
the performance of the PCR method in each experiment.
To avoid contamination by PCR products, sample prepa-
ration and the amplification reaction were all performed in
separate rooms.
(ii) HPV detection by DEIA. The presence of HPV DNA
was determined by hybridization of SPF10 amplimers to a
mixture of general HPV probes recognizing a broad range of
high-risk, low-risk and possible high-risk HPV genotypes in
a microtiter plate format, as described previously. All HPV
DNA positive samples (by SPF10 DEIA) were genotyped
using the HPV SPF10 Line Blot25 genotyping assays.
(iii) HPV genotyping by reverse hybridization using the
HPV SPF10 Line Blot25 genotyping system. The 28 oligo-
nucleotide probes which recognize 25 different types were
tailed with poly(dT) and immobilized as parallel lines to
membrane strips (Labo Bio-medical products B. V. Rijswijk,
The Netherlands). The HPV genotyping assay was per-
formed as described previously. The LiPA strips were
manually interpreted using the provided reference guide.
The samples that tested positive using the DNA Enzyme
Immuno Assay but showed no results on the LiPA strip
were considered to be HPV X-type, i.e., genotypes not
present on the LiPA strip.
To evaluate performance and reproducibility of the anal-
ysis, a quality control program from DDL was performed.
Data analysis
Statistical analyses were performed using the programs
EpiInfo 6.02 (CDC) statistical program, Excell and
LogXact version 4 (Cytel, Cambridge Ma).
Univariate statistics were calculated for all variables.
Any p value less than 0.05 was considered significant.
Odds ratios (ORs) and 95% confidence intervals (CIs) were
obtained from multiple logistic regression models to eval-
uate the association between HPV infections and risk fac-
tors. Variables found to be significantly related to HPV
infection by univariate analyses were entered into a mul-
tiple logistic regression model. We adjusted for age using
five groups contrasted as dummy variables 18–24, 25–34,
35–44, 45–54, and 55–65) and for HPV infection status
(only low risk types and any high risk types). We investi-
gated the potential association with education, socioeco-
nomic status, exposure to wood smoke, history of
pregnancy, parity, age at first intercourse, lifetime number
of sexual partners, number of previous screens, time since
last Pap smear, history of sexually transmitted diseases,
and occurrence of other genital infections that could
influence the development of SIL. The variables that
remained in the final multivariate models were: age,
women’s education, socioeconomic status, time since last
Pap smear, and number of sexual partners.
Results
Among the 591 women with normal cytology enrolled in
this study, 29 were negative for the b-globin PCR and were
eliminated from the study; from the remaining 562 sam-
ples, 289 (51%) were positive for HPV DNA. Overall,
single genotypes were found in 67% of the 289 HPV
positive women (36% of the entire sample) and multiple
genotypes were detected in 33% of the HPV positives
women (15.8% of total).
Twenty-three HPV types were ascertained; HPV 16
(25%), HPV 18 (12%), HPV 51 (10%), HPV 31 (8%), and
HPV 11 (8%) were the most common types identified
(Fig. 1).
Figure 2 shows the age-specific prevalence of HPV
detection. HPV DNA was detected in 58% of women aged
less than 25 years, with prevalence decreasing in older
women to a minimum of 30% among women older than 55.
Overall of the 51% HPV positive women, 35.7% were
infected with high risk (HR) types and 15.3% with low risk
(LR) types only. Women who were infected with both HR/
LR types were grouped as HR types. HR HPV age—specific
prevalence was highest among women below age 25
(46.5%), and again lowest among women aged 55 or more
years (22.7%; Fig. 3).
When considering all HPV types and all age groups
combined, besides the association with age, we observed a
trend for HPV infection and the lifetime number of sexual
partners (Table 1). The only other factors that remained
significant were having a low socioeconomic status (SES)
and less than five previous Pap smears, and women who
had six or more previous screens had a reduced risk of
HPV infection. In HPV positive women, risk factors for
detection of single and multiple HPV infections for all
types were analyzed (Table 2). A total of 200 (69%) of 289
HPV-positive women had a single infection, whereas 89
women (31%) had multiple HPV type detected. For single
HPV infection, the highest prevalence was found among
women less than 25 years (48.8%), whereas for multiple
infections the highest percentage was observed in women
between 25 and 34 years (19.3%). Both single and multiple
infections were associated with low socioeconomic status
(SES) and with reporting more than one lifetime sexual
partner. When analyzing the number of previous screens,
an OR of 1.9, for women who had undergone cytological
screening 6–10 month prior to the interview, was observed.
Cancer Causes Control (2009) 20:1663–1670 1665
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A stronger association was found in the women with
multiple HPV infection that had the last Pap smear taken
0–5 months before (OR = 2.6).
When doing multivariate logistic regression analysis, a
statistically significant association for HPV infection was
ascertained for the women who had a low SES (OR = 1.8,
95%CI = 1.2–2.5).
Risk of HPV infection was reduced for women who
were 45 years or older and had only one lifetime sexual
partner (OR = 0.7, 95%CI = 0.5–1.0).
Discussion
In our survey, the prevalence of genital HPV infections in
the studied population was very high (51%) when com-
pared to what has been reported internationally. It is higher
than the prevalence found among women with normal
cytology in several other Latin American countries: Costa
Rica (16%), Mexico (14.5%), Colombia (14.9%), and
Chile (14.0%) but similar to the one observed previously in
Honduras (39%) considering that in the present study a
more sensitive PCR detection system was used [13, 15–18].
As it happens in most developing countries, in Honduras
some cultural factors can be related to this high HPV
prevalence, especially lack of education; early start of
sexual activity; multiparity; and the prevalence of attitudes,
misconceptions and beliefs that constrain people from
discussing diseases of the genital tract. In most developing
countries, access to health services is limited and screening
for cervical cancer either is nonexistent or reaches few of
the women who need it. A well-functioning health system,
with the necessary equipment and trained providers, is
essential for prevention activities, screening and diagnosis,
linkages for follow-up and treatment, and palliative care.
[7, 9, 10, 12, 13, 15].
Fig. 1 Prevalence of individual
HPV types among Honduran
women with normal cytology
Fig. 2 HPV prevalence in Honduran women with normal cytology
according to age
Fig. 3 Prevalence of high- and low-risk HPV detection among
Honduran women
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Twenty-three different HPV types were detected in
women in this study, which confirmed that there is great
variability in the range of HPV types detected in exfoli-
ated cervical cells at a population level in Latin America
[15, 19, 20].
As was seen in previous studies examining prevalence
of various HPV types among large numbers of women
presenting for reasons other than cervical neoplasia or
known gynecologic problems, we found HPV 16 to be the
most frequently detected HPV type, followed by HPV 18,
HPV 51, and HPV 31 [16, 21, 22]. In a Colombian-based
study, HPV 16 was followed by HPV 58, 56, 18, and 51
[17]. In studies of Dutch, Mexican, and British women, the
second most frequently detected HPV type was HPV 31,
whereas among Brazilian women and women in the United
States, HPV 53 was detected most frequently after HPV 16
[21]. In the Costa Rican population, oncogenic types 58,
51, and 52 were also relatively abundant, followed by types
31 and 18 [15]. It seems that the family of HPV 50s is
common in Latin America and should be considered when
developing HPV vaccines tailored to this population.
A slightly higher prevalence of infection was found in
women less than 25 years, with a strong predominance of
cancer-associated HPV types and single HPV infections.
Table 1 Risk factors for HPV DNA detection among Honduran asymptomatic women
HPV positive (289) Low-risk HPV types High-risk HPV types
% OR % OR % OR
Age (years)
\25 4.4 3.31 0.2 0.86 3.6 3.44
25–34 16.9 2.80 1.8 1.91 11.4 2.45
35–44 16.9 2.94 1.9 2.21 12.3 2.78
45–54 10.9 2.20 1.8 2.35 7.1 1.88
[55 2.3 1.00 0.4 1.00 1.8 1.00
Women0s education (years)
C7 19 1.00 4.7 1.00 15.8 1.00
\7 32 1.05 (0.78–1.41) 7.3 0.99 (0.53–1.85) 27.0 1.08 (0.78–1.49)
Socioeconomic status
Medium 15.1 1.00 4.6 1.00 10.8 1.00
Low 35.6 1.28 (0.88–1.85) 6.6 0.78 (0.35–1.71) 30.7 1.54 (1.01–2.37)
Exposure to wood smoke
No 18.0 1.00 5.7 1.00 13.5 1.00
Yes 35.2 0.79 (0.53–1.16) 6.4 0.45 (0.21–0.99) 30.6 0.91 (0.59–1.40)
Parity
0–3 33.7 1.00 7.8 1.00 26.7 1.00
C4 19.1 0.72 (0.50–1.05) 4.8 0.79 (0.35–1.74) 17.8 0.84 (0.56–1.27)
Age at first intercourse
[18 22 1.00 6.0 1.00 16.0 1.00
B18 31 0.95 (0.66–1.36) 6.0 0.67 (0.31–1.45) 27.3 1.14 (0.76–1.71)
Lifetime number of sexual partners
1 23.7 1.00 6.7 1.00 20 1.00
[1 29.4 1.33 (0.93–1.90) 5.3 0.85 (0.39–1.84) 24.5 1.35 (0.91–2.00)
History of oral contraceptive use
No 17.6 1.00 5.2 1.00 28.3 1.00
Yes 32.7 1.05 (0.73–1.52) 9.2 2.20 (1.01–4.79) 13.5 0.93 (0.62–1.41)
No. previous screens
[10 6.2 1.00 2.5 1.00 3.5 1.00
6–10 17.8 1.04 4.4 0.62 14.2 1.47
0–5 29.2 1.42 5.5 0.64 26.2 2.27
Time since last Pap smear (months)
0–11 40 1.00 7.9 1.00 10.4 1.00
C12 13.2 0.94 (0.61–1.43) 4.5 1.62 (0.70–3.70) 33.0 0.88 (0.55–1.42)
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HPV detection decreases among the women over 55 years
(Fig. 2). This result has been interpreted as an indicator of
the sexual transmission as it coincides with the initiation of
sexual activity. It is a known fact that HPV prevalence
decreases with age, as has been shown in several studies of
younger women [23–25].
We did not find a second peak of HPV after 55 years of
age as observed in a cohort study being conducted in Gua-
nacaste, Costa Rica [15], in Morelos, Mexico [16], Our
results are well in accordance with Cuschiere et al. [26], who
did not find a second peak in peri-menopausal women in a
survey conducted in Edinburgh and with Beby-Defaux et al.
[27] in women who attended a Health Examination Center of
the French social security; they observed that HPV preva-
lence gradually decreased with age. Differences in HPV
DNA prevalence found in different studies, overall and by
age, may be partly accounted for by differences in cohort
effects and PCR methods used for HPV detection. In our
study, it could also be that the group of women over 55 years
was too small (13 women) to exhibit a second peak.
The presence of multiple infections (33%) was higher
than previously observed among control subjects in the
IARC studies done in the Philippines (14.3%), [28] Thailand
(9.8%) [29], Morocco (5.3%) [30], Paraguay (16.7%) [22],
Table 2 Risk factors for HPV DNA single and multiple detection among Honduran asymptomatic women
HPV single detection (n = 183) HPV multiple detection (n = 93)
% OR % OR
Age (years)
\25 7.4 5.74 1.5 0.98
25–34 19.5 3.38 12.5 1.86
35–44 23.2 4.23 9.6 1.50
45–54 15.1 3.21 6.6 1.21
[55 2.2 1.00 2.6 1.00
Women’s education (years)
C7 15 1.00 9.0 1.00
\7 25.5 1.07 (0.77–1.49) 16.4 1.14 (0.75–1.75)
Socioeconomic status
Medium 10.6 1.00 8.0 1.00
Low 28.6 1.47 (0.95–2.28) 17.2 1.16 (0.68–1.99)
Exposure to wood smoke
No 14.6 1.00 8.2 1.00
Yes 27.1 0.74 (0.48–1.15) 18.8 0.92 (0.53–1.60)
Parity
0–3 26.2 1.00 16.1 1.00
C4 16.0 0.78 (0.51–1.19) 11.5 0.90 (0.54–1.53)
Age at first intercourse
[18 18.0 1.00 9.8 1.00
B18 23.6 0.88 (0.58–1.33) 16.9 1.16 (0.68–1.96)
Lifetime number of sexual partners
1 19.0 1.00 11.4 1.00
[1 22.5 1.27 (0.85–1.91) 15.5 1.46 (0.88–2.44)
History of oral contraceptive use
No 24.3 1.00 17.0 1.00
Yes 15.0 1.20 (0.79–1.82) 8.2 0.95 (0.55–1.61)
No. previous screens
[10 9.2 1.00 2.3 1.00
6–10 21.8 0.86 11.9 1.87
0–5 34.9 1.14 19.9 2.61
Time since last Pap smear (months)
0–11 31.0 1.00 20.8 1.00
C12 10.5 0.96 (0.59–1.55) 6.5 0.89 (0.48–1.63)
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and The Netherlands (28%) [21], but lower than in a popu-
lation-based study from Costa Rica (39%) [15] and similar
to the results from a study done in Colombia (29.7%) [17].
The extent and importance of multiple HR-HPV infections
in the progression of cervical neoplasia and its management
remain unknown. Some studies have described multiple
HR-HPV infections to be most prevalent in young women
and to be more frequent in low grade than in high grade
cervical neoplasia, which could reflect common sexual
transmission of multiple HR-HPV [22, 26, 31, 32]. On the
other hand, Bachtiary et al. [33] demonstrated that the
presence of multiple HPV types is associated with poor
response and with reduced survival in cervical cancer
patients who receive radiotherapy as the primary treatment.
We explored risk factors for acquiring HPV infection and
found that the number of sexual partners was weakly related
to HPV infection, in contrast to what has been demonstrated
in previous studies [34–36] and not well in accordance with
data described before in Honduran women [37]. This could
be the result of bias, since for cultural reasons women might
not tell the real number of sexual partners or it could be
explained by the predominance of ‘‘male role’’ in the
transmission of HPV infections to women committed to one
sexual partner. In this context, a woman’s risk of cervical
cancer may depend less on her own sexual behavior than on
that of her husband or other male partners. Unfortunately,
no information was available on the sexual behavior of the
partners in our study population.
In the present study there was no association between
HPV infection and the use of wood for cooking, consid-
ering that bias could have been introduced when they
answered the question and the time of exposure to wood
smoke was not measured. On the other hand, Ferrera et al.
[37] found in a case–control study performed in Honduran
women, a strong association between the use of wood as
cooking fuel for many years and cervical cancer even after
adjustment for education, strongly suggesting that exposure
to wood smoke is not just an indicator of SES, but inclined
them to believe that there could be a biologic effect.
Our results also showed that there was an association of
HPV infection with number of previous screens, especially
for multiple infections, in which women who had less than
five previous screens had a two times higher risk of HPV
infection than women who had more than 10 previous
screens, supporting the preponderant role of cervical
screening in the effective control of cervical cancer. This is
in complete concordance with previous findings in Hon-
duran women in a case–control study; cytological screen-
ing conferred a protective effect [13]. Prospective studies
are required to assess the impact of multiple HR-HPV
infections on neoplastic progression.
There are limitations in the design of the study; one of
them is the small sample size, especially in women over
55 years of age. As a health care center-based study, there
is a potential bias related to the selection of the study
subjects, as they were primarily seeking cervical cancer
screening services. It would be necessary to compare some
of the variables, like the education level of women par-
ticipating in the study with women in the general popula-
tion to see how representative the sample of women
participating in the study is of the general population.
The recent approval by the US FDA and the European
EMEA of an HPV vaccine to prevent high-risk HPV
infection and development of cervical cancer represents a
major landmark to eliminate the suffering and death due to
cancer, reduce the need for costly medical procedures and
provide both women and communities throughout the
world with substantial benefits. HPV 16–18 vaccination
will prevent HPV 16–18 incident infection, and subse-
quently decrease in 90% the frequency of abnormal Pap
attributable to these types and in about 50% overall
abnormal Pap [38]. Besides, HPV vaccination will reduce
the number of women who require colposcopy, biopsy, and
cervical treatment for precancerous cervical lesions [39].
To maximize the cost-effectiveness of a HPV vaccina-
tion programmes, it is important to understand the distri-
bution of the major HPV types in various geographic
regions. The results emanating from this research may
assist the public health authorities in planning prophylactic
and therapeutic strategies to prevent cervical cancer,
including HPV diagnosis and rational vaccine strategies.
The establishment of a well-characterized population with
regard to the community prevalence of type-specific HPV
infection will provide a valuable baseline for monitoring
population effectiveness of an HPV vaccine.
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